Home › Mild Cognitive Impairment › NCT03372317
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
Tau Positron Emission Tomography (PET) in Imaging and Cognition
Who can join
Ages 55 to 90 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Aged 55-90 * Previously received an amyloid PET scan * Residing near Columbia University Medical Center * Must be willing and able to participate Exclusion Criteria: * Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour) * Pregnancy * Lactating Women * Current, past, or anticipated exposure to radiation * Significant active physical illness
About the study
The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.
What is being tested
- 18F-MK-6240 (drug)
Sponsor: Yaakov Stern · Participants: 105 · Started: Jun 1, 2018
Contact the study team
- Reshma Babukutty · Phone: 212-305-6314
Official record on ClinicalTrials.gov — NCT03372317
Locations in the U.S.
| New York | Columbia University Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.